Information on the total number of voting rights and shares (Article 15 of the Law of 2 August 2007)

Mont-Saint-Guibert, Belgium, 11 July, 2013 - The biotechnology company, Cardio3 BioSciences SA (Cardio3 BioSciences), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it has received a transparency declaration from Tolefi SA, Participatie Maatschappij Vlanderen (PMV) NV, Sofipole SA and Mayo Foundation for Medical Education and Research in accordance with the Belgian Law of 2nd May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market.

As of today, the Company’s share capital amounts to EUR 21,412,720.43 and is represented by a total 6,125,567 shares (each share given one voting right).

Transparency notification from Tolefi SA

Cardio3 BioSciences received on July 11, 2013 notification of transparency arising from Tolefi SA having passed, on July 9, 2013, the 35% threshold.

  • Reason for notification: an ownership interest at the time of the IPO
  • Notification by a parent company or controlling person.
  • Person (s) holding (s) notification:
Name Address
Tolefi SA TOLEFI SA Drève of Carloo 27, 1180 Brussels
Serge GOBLET 48 Golf Avenue, 1640 Rhode Saint Genese
Isabelle THOUMYRE 48 Golf Avenue, 1640 Rhode Saint Genese

Tolefi SA is a family holding company 100% owned by Mr. Serge Goblet and his wife Isabelle Thoumyre. The company also holds 2,504 warrants giving 2504 voting rights

Transparency notification from Participatie Maatschappij Vlanderen NV

Cardio3 BioSciences received on July 10 2013, a transparency notification from Participatie Maatschappij Vlanderen NV, having passed, on July 5, 2013, the 5% threshold.

  • Reason for notification: an ownership interest at the time of the IPO
  • Notification by a parent company or controlling person.
  • Person (s) holding (s) notification


 

Name Address
Participatiemaatschappij Vlaanderen NV (PMV NV) Oude Graanmarkt 63, 1000 Brussels
PMV-TINA Comm VA Oude Graanmarkt 63, 1000 Brussels
Het Vlaams Gewest Martelaarsplein 19, 1000 Brussels

Participatiemaatschappij Vlaanderen NV controls PMV-Tina Comm VA.

Transparency notification from SRIW SA/Sofipole SA

Cardio3 BioSciences, received on July 9 2013, a transparency notification from SRIW SA/Sofipole, having passed, on July 5, 2013, the 10% threshold.

  • Reason for notification: an ownership interest at the time of the IPO
  • Notification by a parent company or controlling person.
  • Person (s) holding (s) notification
Name Address
S.R.I.W SA avenue Maurice Destenay 13, 4000 Liège
SOFIPOLE SA avenue Maurice Destenay 13, 4000 Liège

The Walloon Region owns 98.65% of SRIW SA, which owns 60% of shares in SOFIPOLE SA.

Transparency notification from Mayo Foundation for Medical Education and Research

Cardio3 BioSciences received July 9, 2013 a transparency notification from the Mayo Foundation for Medical Education and Research, having passed on July 5, 2013, the 5% threshold.

  • Reason for notification: an ownership interest at the time of the IPO
  • Notification by a parent company or controlling person.
  • Person (s) holding (s) notification
Name Address
Mayo Foundation for Medical Education and Research  200 First Street SW, Rochester, MN 55906-001 (United States of America)

Mayo Foundation for Medical Education and Research is not a controlled entity.

Download press release(s)

Communiqué de presse

147.36 Ko

Press release

126.74 Ko

Cardio3 BioSciences: Exercise of Over-allotment Option Total proceeds from the IPO €26.5m

Next News

Cardio3 BioSciences: Exercise of Over-allotment Option Total proceeds from the IPO €26.5m